Biotechs Get Rival Deals To Build Anthrax Vaccine

The Washington Post reports on $113.6 million in government contracts to develop new anthrax vaccines. Two rival biotechs — Emergent BioSolutions of Rockville and PharmAthene of Annapolis — announced yesterday that they received separate federal development contracts. This is further evidence that, despite a $448 million contract landed by Emergent to supply 18.75 million doses of anthrax vaccine, the Emergent/Bioport vaccine is unsatisfactory and must be replaced–primarily due to its weak efficacy, required yearly boosters and frequent serious (and permanent) side effects.

Notify of
Inline Feedbacks
View all comments
Scroll to Top